Innate Pharma Statistics

Total Valuation

Innate Pharma has a market cap or net worth of EUR 185.24 million. The enterprise value is 135.46 million.

Market Cap	185.24M
Enterprise Value	135.46M

Important Dates

The next estimated earnings date is Wednesday, September 17, 2025.

Earnings Date	Sep 17, 2025
Ex-Dividend Date	n/a

Share Statistics

Innate Pharma has 92.16 million shares outstanding. The number of shares has increased by 0.74% in one year.

Current Share Class	92.16M
Shares Outstanding	92.16M
Shares Change (YoY)	+0.74%
Shares Change (QoQ)	+0.44%
Owned by Insiders (%)	2.18%
Owned by Institutions (%)	2.38%
Float	34.42M

Valuation Ratios

PE Ratio	n/a
Forward PE	2.72
PS Ratio	9.21
PB Ratio	20.97
P/TBV Ratio	20.97
P/FCF Ratio	n/a
P/OCF Ratio	n/a
PEG Ratio	n/a

Financial Ratio History

Enterprise Valuation

EV / Earnings	-2.74
EV / Sales	6.73
EV / EBITDA	n/a
EV / EBIT	n/a
EV / FCF	-18.59

Financial Position

The company has a current ratio of 2.60, with a Debt / Equity ratio of 3.51.

Current Ratio	2.60
Quick Ratio	2.50
Debt / Equity	3.51
Debt / EBITDA	n/a
Debt / FCF	-4.25
Interest Coverage	-91.12

Financial Efficiency

Return on equity (ROE) is -162.91% and return on invested capital (ROIC) is -48.98%.

Return on Equity (ROE)	-162.91%
Return on Assets (ROA)	-22.52%
Return on Invested Capital (ROIC)	-48.98%
Return on Capital Employed (ROCE)	-66.06%
Revenue Per Employee	111,166
Profits Per Employee	-273,320
Employee Count	181
Asset Turnover	0.14
Inventory Turnover	n/a

Taxes

Income Tax	n/a
Effective Tax Rate	n/a

Stock Price Statistics

The stock price has decreased by -10.40% in the last 52 weeks. The beta is 0.94, so Innate Pharma's price volatility has been similar to the market average.

Beta (5Y)	0.94
52-Week Price Change	-10.40%
50-Day Moving Average	1.87
200-Day Moving Average	1.87
Relative Strength Index (RSI)	62.08
Average Volume (20 Days)	120,915

Short Selling Information

Short Interest	n/a
Short Previous Month	n/a
Short % of Shares Out	n/a
Short % of Float	n/a
Short Ratio (days to cover)	n/a

Income Statement

In the last 12 months, Innate Pharma had revenue of EUR 20.12 million and -49.47 million in losses. Loss per share was -0.61.

Revenue	20.12M
Gross Profit	-31.86M
Operating Income	-51.58M
Pretax Income	-49.47M
Net Income	-49.47M
EBITDA	-50.27M
EBIT	-51.58M
Loss Per Share	-0.61

Full Income Statement

Balance Sheet

The company has 80.77 million in cash and 31.00 million in debt, giving a net cash position of 49.78 million or 0.54 per share.

Cash & Cash Equivalents	80.77M
Total Debt	31.00M
Net Cash	49.78M
Net Cash Per Share	0.54
Equity (Book Value)	8.83M
Book Value Per Share	0.11
Working Capital	52.76M

Full Balance Sheet

Cash Flow

In the last 12 months, operating cash flow was -6.90 million and capital expenditures -391,000, giving a free cash flow of -7.29 million.

Operating Cash Flow	-6.90M
Capital Expenditures	-391,000
Free Cash Flow	-7.29M
FCF Per Share	-0.08

Full Cash Flow Statement

Margins

Gross margin is -158.34%, with operating and profit margins of -256.32% and -245.87%.

Gross Margin	-158.34%
Operating Margin	-256.32%
Pretax Margin	-245.87%
Profit Margin	-245.87%
EBITDA Margin	-249.86%
EBIT Margin	-256.32%
FCF Margin	n/a

Dividends & Yields

Innate Pharma does not appear to pay any dividends at this time.

Dividend Per Share	n/a
Dividend Yield	n/a
Dividend Growth (YoY)	n/a
Years of Dividend Growth	n/a
Payout Ratio	n/a
Buyback Yield	-0.74%
Shareholder Yield	-0.74%
Earnings Yield	-26.71%
FCF Yield	-3.93%

Stock Splits

This stock does not have any record of stock splits.

Last Split Date	n/a
Split Type	n/a
Split Ratio	n/a

Scores

Innate Pharma has an Altman Z-Score of -4.65. A Z-score under 3 suggests an increased risk of bankruptcy.

Altman Z-Score	-4.65
Piotroski F-Score	n/a